Companies wanting to compete in the newly off-patent adalimumab market in England have until Oct. 22 to submit their bids. They will need to offer “competitive prices” if they are to secure the highest share of sales to the national health service. At the same time, NHS trusts and clinical commissioning groups have been warned not to accept discounted interim offers from suppliers keen to get a foot in the door.
Companies wanting a share of the lucrative adalimumab market in England following the expiry of patent protection on AbbVie Inc.’s Humira will need to offer a "competitive price". They have just a few days in which to do so.
Biosimilar versions of adalimumab are expected to be made available under the National Health Service in England starting on Dec....